GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Cyclically Adjusted PB Ratio

Prothena (Prothena) Cyclically Adjusted PB Ratio : 1.92 (As of May. 02, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Cyclically Adjusted PB Ratio?

As of today (2024-05-02), Prothena's current share price is $21.42. Prothena's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $11.16. Prothena's Cyclically Adjusted PB Ratio for today is 1.92.

The historical rank and industry rank for Prothena's Cyclically Adjusted PB Ratio or its related term are showing as below:

PRTA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.82   Med: 4.64   Max: 8.54
Current: 1.82

During the past years, Prothena's highest Cyclically Adjusted PB Ratio was 8.54. The lowest was 1.82. And the median was 4.64.

PRTA's Cyclically Adjusted PB Ratio is ranked worse than
53.42% of 644 companies
in the Biotechnology industry
Industry Median: 1.74 vs PRTA: 1.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Prothena's adjusted book value per share data for the three months ended in Dec. 2023 was $10.457. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $11.16 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Prothena Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Prothena's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Cyclically Adjusted PB Ratio Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.13 5.79 3.26

Prothena Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.79 4.53 6.22 4.31 3.26

Competitive Comparison of Prothena's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Prothena's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Prothena's Cyclically Adjusted PB Ratio falls into.



Prothena Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Prothena's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=21.42/11.16
=1.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Prothena's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=10.457/120.1096*120.1096
=10.457

Current CPI (Dec. 2023) = 120.1096.

Prothena Quarterly Data

Book Value per Share CPI Adj_Book
201403 8.811 100.573 10.523
201406 11.192 100.773 13.340
201409 11.013 100.474 13.165
201412 10.585 99.576 12.768
201503 10.101 99.975 12.135
201506 12.595 100.573 15.042
201509 11.990 100.274 14.362
201512 11.362 99.676 13.691
201603 13.564 99.676 16.345
201606 12.532 101.072 14.893
201609 11.641 100.274 13.944
201612 10.515 99.676 12.671
201703 13.074 100.374 15.645
201706 12.762 100.673 15.226
201709 11.608 100.474 13.877
201712 10.581 100.075 12.699
201803 10.283 100.573 12.280
201806 8.938 101.072 10.622
201809 8.520 101.371 10.095
201812 8.103 100.773 9.658
201903 7.830 101.670 9.250
201906 7.590 102.168 8.923
201909 7.248 102.268 8.513
201912 6.840 102.068 8.049
202003 6.390 102.367 7.498
202006 5.874 101.769 6.933
202009 5.248 101.072 6.237
202012 4.609 101.072 5.477
202103 5.310 102.367 6.230
202106 6.417 103.364 7.457
202109 10.540 104.859 12.073
202112 9.988 106.653 11.248
202203 9.388 109.245 10.322
202206 8.701 112.734 9.270
202209 8.450 113.431 8.947
202212 11.939 115.425 12.424
202303 11.531 117.618 11.775
202306 10.874 119.611 10.919
202309 11.507 120.708 11.450
202312 10.457 120.110 10.457

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Prothena  (NAS:PRTA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Prothena Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Prothena's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena (Prothena) Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453

Prothena (Prothena) Headlines